We leverage our preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits us to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.
This press release contains "forward-looking statements" (within the
meaning of the Private Securities Litigation Act of 1995) that inherently
involve risk and uncertainties. Champions Biotechnology generally uses
words such as "believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify forward-looking
statements. One should not place undue reliance on these forward-looking
statements. The Company's actual results could differ materially from those
anticipated in the forward-looking statements for many unforeseen factors.
See Champions Biotechnology's Form 10-KSB for the fiscal year ended April
30, 2007 for a discussion of such risks, uncertainties and other factors.
Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of
the date on which the statements are made, and
|SOURCE Champions Biotechnology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved